3 completed, 1 enrolling by invitation, 1 unknown. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Enrolling by invitation 1, Unknown 1 |
Follow Schizophrenia, Paranoid: new trials by email Literature Review of Schizophrenia, Paranoid trials Research Report on Schizophrenia, Paranoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement Rituximab - Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior | Phase 2 | Enrolling by invitation | Uppsala University Hospital | 40 | 2022-05-01 | 2024-11-19 |
| Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia t-VNS verum, t-VNS placebo - Schizophrenia | Phase 2 | Completed | cerbomed GmbH | 20 | 2010-03-01 | 2012-09-12 |
| MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016) MK0249, Comparator: Placebo (unspecified) - Paranoid Schizophrenia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 55 | 2007-12-01 | 2015-08-03 |
| MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027) MK0557, Comparator: Placebo (unspecified) - Paranoid Schizophrenia, Schizophrenia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 50 | 2007-09-01 | 2015-08-21 |
| Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis modified cognitive behavioural therapy (mCBT) - Psychotic Disorders, Schizophrenia | Phase 2 | Unknown | University of Cologne | 42 | 2007-05-01 | 2009-02-20 |
Schizophrenia (4) · Psychotic Disorders (3) · Mental Disorders (2) · Compulsive Behavior (1) · Delusions (1) · Dementia (1) · Hallucinations (1) · Illusions (1) · Neuroleptic Malignant Syndrome (1) · Obsessive-Compulsive Disorder (1) · Schizophrenia, Catatonic (1) · Schizophrenia, Disorganized (1) · Tardive Dyskinesia (1)
Schizophrenia Spectrum and Other Psychotic Disorders (5) · Mental Disorders (3) · Behavior (2) · Anxiety Disorders (1) · Basal Ganglia Diseases (1) · Behavioral Symptoms (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Chemically-Induced Disorders (1) · Dyskinesia, Drug-Induced (1) · Dyskinesias (1) · Impulsive Behavior (1) · Movement Disorders (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1)
MK-0249 (1) · Rituximab (1) · spiro(cyclohexane-1,3'(1'H)-furo(3,4-C)pyridine)-4-carboxamide, N-(1-(2-fluorophenyl)-1h-pyrazol-3-yl)-1'-oxo-, trans- (1)
Merck Sharp & Dohme LLC (2) · University of Cologne (1) · Uppsala University Hospital (1) · cerbomed GmbH (1)
Germany (2) · Sweden (1)
Andreas Bechdolf, PD Dr. (1) · Janet L Cunningham, MD PhD (1)
2019 (1)